Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
【Daiichi Sankyo Dedabotumab Approved In Japan To Treat Breast Cancer】On December 27, Local Time, Daiichi Sankyo Announced That The Targeted Trop2 Antibody-Conjugate Drug (Adc) Datroway (Datopotamab Deruxtecan, Dedabotumab) Jointly Developed By The Company And Astrazeneca (Astrazeneca) Has Been Approved In Japan For The Treatment Of Hormone-Positive (Hr) -Positive, Human Epidermal Growth Factor Receptor 2 (Her2) Negative (Ihc 0, Ihc 1+ Or Ihc 2+/Ish-) Mastectomized Adults After Undergoing Chemotherapy Patients
Quick access to 24/7
Quick access to more editor-selected real-time news
Exclusive video for free
FastBull VIPject team is dedicated to create exclusive videos
Follow More Symbols
You can add more symbols to your watchlist.
More comprehensive macro data and economic indicators
More comprehensive historical data on indicators to help analyze macro markets
Member-only Database
Comprehensive forex, commodity, and equity market data